Larry Allen, MD: “There was benefit on the secondary outcomes of...

Larry Allen, MD:

“There was benefit on the secondary outcomes of nonfatal MI or stroke, but these are not the outcomes we follow in heart failure patients,”

Most likely these outcomes (nonfatal MI or stroke) are not followed in heart failure patients because there to date is no meaningful therapy to address this aspect of the disease - with the exception now being the amazing data from Rex-L of course.

"For the patient, it is “more important to double down on the importance of guideline directed medical therapy,” which is still being administered at levels that are suboptimal'

Yes however what he fails to realise IMO is that Rex-L will be added to SOC addressing the fluid overload aspect of CHF. Rex-L can be added on top of this SOC to address the disease progression (smouldering inflammation) aspect of CHF.

Pretty sure improvements in terms of nonfatal MI or stroke can not be ignored by treating physicians and the FDA. What's more it is not disrupting to big pharma because it is an add on therapy.